Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial.


Journal

International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 23 04 2019
accepted: 27 04 2020
pubmed: 23 5 2020
medline: 16 6 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Background Pulmonary hypertension is a rare, chronic and life-threatening group of diseases. Recent advances in pulmonary hypertension management prolong survival and improve quality-of-life. However, highly complex drug therapy enhances the risk of drug-related problems. Objective To assess the impact of involving clinical pharmacists in the collaborative care of pulmonary hypertension patients. Setting Ten French University Hospital Pneumology departments, all members of the French Network for Pulmonary Hypertension. Methods This prospective multicenter randomized controlled trial included incident pulmonary hypertension patients who were followed-up for 18 months. Randomization using an adapted Zelen method allocated patients to collaborative care (n = 41) or usual care groups (n = 51). A collaborative care program involving clinical pharmacists was developed through a close partnership between with physicians, nurses and pharmacists. Besides usual care, the program includes regular one-to-one interviews between the pharmacist and the patient. These interviews had following objectives: to perform an exhaustive medication history review; to identify the patient' needs, knowledge and skills; to define educational objectives and to provide patients with relevant information when needed. Following each interview, a standardized report form containing the pharmacist's recommendations was provided to physicians and nurses and discussed collaboratively. An ancillary economic analysis was performed. Main outcome measure Number of drug-related problems and their outcomes. Results The number of drug-related problems was not significantly different between groups (1.6 ± 1.5 vs. 1.9 ± 2.4; p = 0.41). More problems were resolved in the collaborative care group than in the usual care group (86.5% vs. 66.7%, p = 0.01). Time to clinical worsening, therapeutic adherence, satisfaction or quality-of-life were not statistically different between groups. Collaborative care decreased costs of drug-related hospitalizations. Conclusion Including clinical pharmacists in the multidisciplinary care of hospitalized patients with pulmonary hypertension improved the outcome of drug-related problems and reduced the costs of related hospitalization. However, we observed no efficacy on medication errors, clinical outcomes or medication adherence. Clinical Trial Registration ClinicalTrials.gov Identifier NCT01038284.

Identifiants

pubmed: 32440738
doi: 10.1007/s11096-020-01047-8
pii: 10.1007/s11096-020-01047-8
doi:

Banques de données

ClinicalTrials.gov
['NCT01038284']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1128-1138

Investigateurs

Claire Dromer (C)
Séverine Duconge (S)
Alan Glavieux (A)
Marie-Claude Saux (MC)
Sami Yeni (S)
Christelle Demeyer (C)
Irène Frachon (I)
Philippe Lorillon (P)
Anne Bastin (A)
Hélène Bouvaist (H)
Boubou Camara (B)
Céline Chat (C)
Marie Coste (M)
Marion Delamare (M)
Nicolas Gonnet (N)
Marie Jondot (M)
Marion Lepelley (M)
Adrien Lotito (A)
Sébastien Quetant (S)
Emmanuelle Odin (E)
Christel Robert (C)
Christel Saint Raymond (CS)
Muriel Salvat (M)
Carole Saunier (C)
Stéphanie Belaiche (S)
Eric Hachulla (E)
Marie-Noelle Lefebvre (MN)
Géraldine Wojtasik (G)
Pierre Chauvet (P)
Catherine Creach (C)
Isabelle Danner (I)
Nadia Fayad (N)
David Feldman (D)
Alain Haloun (A)
Alexandra Trainaud (A)
Valérie Viaud (V)
Aline Babin (A)
Alexia Le Duff (A)
Franck Lemoigne (F)
Katia Muller (K)
Isabelle Bruère (I)
Hélène Coulon (H)
Marc Humbert (M)
Xavier Jaïs (X)
Marion Jobard (M)
Marie-Catherine Lott (MC)
David Montani (D)
Laurent Savale (L)
Gérald Simmoneau (G)
Fabrice Bauer (F)
Emmanuelle Benmokhtar (E)
Estelle Huet (E)
Sandrine Philippe (S)
Remi Varin (R)
Matthieu Canuet (M)
Thomas Wolff (T)
Daniel Antier (D)
Isabelle Crenn (I)
Elisabeth Collet (E)
Delagarenne Anne (D)
Pascal Magro (P)

Auteurs

Matthieu Roustit (M)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France. MRoustit@chu-grenoble.fr.
INSERM U1042- HP2 Laboratory, 38000, Grenoble, France. MRoustit@chu-grenoble.fr.
Clinical Pharmacology- INSERM CIC1406, Research Division, Grenoble Alpes University Hospital, 38000, Grenoble, France. MRoustit@chu-grenoble.fr.

Marie-Camille Chaumais (MC)

Faculty of Pharmacy, Paris-Sud University, 92290, Châtenay Malabry, France.
Pharmacy Department, DHU Thorax Innovation, Antoine Béclère Hospital, Paris Hospitals, 92140, Clamart, France.
INSERM UMR_S 999, Marie Lannelongue Surgery Center, 92350, Le Plessis Robinson, France.

Claire Chapuis (C)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France.

Anne Gairard-Dory (A)

Pharmacy Department, Strasbourg University Hospital, 67000, Strasbourg, France.

Caroline Hadjadj (C)

Health Products Division, Bordeaux University Hospital, 33600, Pessac, France.

Sébastien Chanoine (S)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France.
INSERM U823 - Albert Bonniot Institute, 38000, Grenoble, France.
CNRS, TIMC-IMAG, 38000, Grenoble, France.

Benoît Allenet (B)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France.
CNRS, TIMC-IMAG, 38000, Grenoble, France.

Olivier Sitbon (O)

INSERM UMR_S 999, Marie Lannelongue Surgery Center, 92350, Le Plessis Robinson, France.
Faculty of Medicine, Paris-Sud University, 94270, Le Kremlin-Bicêtre, France.
Pneumology Department, Bicêtre Hospital, Paris Hospitals, 94270, Le Kremlin-Bicêtre, France.

Christophe Pison (C)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France.
Fundamental and Applied Bioenergetics Laboratory, INSERM U1055, 38000, Grenoble, France.
University Pneumology Clinic, Thorax and Vessels Division, Grenoble Alpes University Hospital, 38000, Grenoble, France.

Pierrick Bedouch (P)

Faculty of Medicine and Pharmacy, Grenoble Alpes University, 38000, Grenoble, France.
CNRS, TIMC-IMAG, 38000, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH